Exudative vitreoretinopathy 1 is a rare genetic eye condition that affects the retina and vision. It often starts in infancy or childhood and can progress over time. People with exudative vitreoretinopathy 1 may have poor night vision, side vision loss, or blurry sight, and doctors may see abnormal blood vessels in the retina. Treatment focuses on monitoring, laser or injections to control leaky vessels, and surgery if the retina detaches. Most people live a normal lifespan, but vision outcomes vary and early symptoms of exudative vitreoretinopathy 1 should prompt an eye exam by a specialist.
Overview
Exudative vitreoretinopathy 1Symptoms
Early signs of Exudative vitreoretinopathy 1 include reduced side or night vision, blurry vision, or vision loss; some have no obvious changes. Some notice eye misalignment or quick eye movements. Doctors may see retinal leakage, folds, or detachments.
Outlook and prognosis
Many living with Exudative vitreoretinopathy 1 have stable vision for years, especially with regular eye checks and timely treatment. Others may see changes during childhood or adolescence that need close follow-up. Early detection and careful monitoring help protect sight.
Causes and risk factors
Exudative vitreoretinopathy 1 is usually caused by pathogenic variants in the FZD4 gene, disrupting retinal vessel growth. It’s typically inherited in an autosomal-dominant pattern, with risk highest in families; new (de novo) mutations occur. No lifestyle causes; severity varies.
Genetic influences
Genetics play a major role in exudative vitreoretinopathy 1. Variants in several eye-development genes can disrupt retinal blood vessel growth, leading to vision problems. Inherited patterns vary (often X‑linked or autosomal dominant), and family history strongly guides testing and counseling.
Diagnosis
Doctors diagnose Exudative vitreoretinopathy 1 through eye examination and imaging showing abnormal retinal vessels. Fluorescein angiography and OCT are commonly used. Genetic tests confirm findings; genetic diagnosis of Exudative vitreoretinopathy 1 also supports family screening.
Treatment and drugs
Exudative vitreoretinopathy 1 care focuses on protecting sight, managing leaks and traction in the retina, and preventing complications. Depending on findings, options include observation, laser or cryotherapy to seal weak vessels, anti-VEGF eye injections, and surgery for detachment or vitreoretinal traction. Regular imaging-guided follow-up and protective glasses help monitor progression and support daily vision.
Symptoms
Exudative vitreoretinopathy 1 is a genetic condition that affects the fine blood vessels of the retina, the light-sensing layer at the back of the eye. Features vary from person to person and can change over time. Early features of Exudative vitreoretinopathy 1 may be subtle, ranging from no obvious issues to changes in side vision or eye alignment. Some people have no vision problems for years, while others notice changes in childhood.
Reading, schoolwork, or recognizing faces can feel harder because details look fuzzy. Focusing may take longer, and brightness or glare can make blurriness more noticeable.
In Exudative vitreoretinopathy 1, missing patches in peripheral vision can develop. People may miss objects coming from the side or have trouble tracking a ball in sports.
Small dark spots that drift or brief light flickers can appear, sometimes more noticeable in dim settings. These can happen when the gel inside the eye tugs on the retina or when tiny bleeds occur.
One eye may turn in or out, which can make depth perception less reliable and reading more tiring. Some children with Exudative vitreoretinopathy 1 are first noticed to have a wandering eye during checkups or in photos.
How people usually first notice Exudative vitreoretinopathy 1?
Many first notice something is off when a child doesn’t track faces or toys well, seems unusually sensitive to light, or one eye drifts (a lazy eye/strabismus), prompting an eye exam. In exudative vitreoretinopathy 1, doctors often first spot the problem during a newborn or early childhood eye check by seeing abnormal blood vessel growth and leakage in the retina, sometimes before symptoms are obvious. In some families, the first signs of exudative vitreoretinopathy 1 are found through screening after a relative is diagnosed, or incidentally during an exam for poor vision, unequal reflexes on a flashlight test, or unexplained retinal detachment.
Types of Exudative vitreoretinopathy 1
Exudative vitreoretinopathy 1 is a genetic eye condition with a spectrum of severity. Vision changes can range from mild peripheral vision loss to significant retinal detachment, sometimes differing even between the two eyes in the same person. People may notice issues from infancy or later in childhood or adulthood, and family members can be affected in different ways. Not everyone will experience every type.
Asymptomatic/mild
Little to no noticeable vision problems in daily life. Eye exams may still show peripheral retinal blood vessel changes. Early symptoms of exudative vitreoretinopathy 1 can be subtle and easy to miss.
Peripheral-predominant
Trouble with side vision more than central detail. Doctors see abnormal vessel growth at the edges of the retina with areas lacking blood supply. Night vision challenges or bumping into objects at the periphery can appear first.
Macula-involving
Blurred central vision or waviness when reading or recognizing faces. Fluid or scarring can affect the macula, the sharp-seeing center. Fine-detail tasks may become difficult even if peripheral vision seems okay.
Exudative changes
Leakage from fragile retinal vessels causes fluid or lipid deposits. This can lead to swelling under the retina and vision distortion. Without treatment, the risk of retinal damage increases.
Tractional detachment
Scar tissue pulls on the retina and can cause parts to lift off. People may see a curtain, arcs of light, or a sudden drop in vision. Urgent care is needed to protect remaining sight.
Neovascular complications
New, fragile vessels form in response to low oxygen in the retina. These can bleed, causing floaters or sudden dark patches. Repeated bleeding raises the risk of scarring and further vision loss.
Asymmetric eyes
One eye may remain mild while the other progresses. This uneven pattern can make changes harder to notice until they are advanced. Regular, dilated exams help catch shifts early.
Childhood-onset
Signs appear in infancy or early childhood, such as crossed eyes, poor tracking, or white pupil reflex in photos. Growth of retinal vessels stalls at the edges, setting up leakage and scarring. Prompt diagnosis can guide monitoring and treatment.
Adult-onset detection
Some are diagnosed later when mild changes are found on routine exam. Symptoms can be subtle, like increased floaters or dim vision in low light. Care focuses on surveillance to prevent complications.
Family variability
Relatives with the same genetic change can have very different severity. Loved ones may recognize certain types sooner than the person experiencing them. Genetic counseling can clarify risks and testing options.
What genetics can tell you about symptoms
Some people with exudative vitreoretinopathy 1 (often linked to FZD4 gene changes) develop peripheral retinal blood vessel gaps, causing fluid leakage, traction, and vision loss or blind spots. Different variants can shift severity, from few floaters and mild night vision trouble to early retinal detachments.
Causes and risk factors
Exudative vitreoretinopathy 1 is caused by a change in the FZD4 gene that affects how blood vessels grow in the retina. The change can be inherited with a 50% chance of passing from an affected parent to each child, or it can appear for the first time. Risk factors for exudative vitreoretinopathy 1 mainly include a family history and a known FZD4 gene change, and severity can vary within the same family. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). Genes drive the condition, but regular eye exams, early care for new eye symptoms, and protecting the eyes from injury may help reduce complications.
Environmental and biological risk factors
Understanding environmental and biological risk factors for Exudative vitreoretinopathy 1 can be confusing, especially when most causes are present before birth. Doctors often group risks into internal (biological) and external (environmental). For this condition, research has not identified clear environmental triggers, and other medical factors appear limited. The points below reflect what is currently known.
No specific chemical, radiation, or infection exposures have been confirmed to increase the likelihood of Exudative vitreoretinopathy 1. Studies to date have not shown consistent links. Ongoing research continues to watch for possible environmental influences.
Common issues such as gestational diabetes, preeclampsia, or infections have not been shown to raise risk. Available data do not support a consistent association. These concerns still matter for overall pregnancy health, but not as clear drivers here.
Unlike conditions tied to prematurity, this diagnosis does not appear to be caused by being born early or having low birth weight. Reports include many full-term births without neonatal complications.
Supplemental oxygen in the newborn period is not known to cause this condition. Evidence does not show an increased risk with routine neonatal oxygen care.
Genetic risk factors
Genetically, Exudative vitreoretinopathy 1 usually traces to a change in the FZD4 gene involved in retinal blood vessel development. Risk is not destiny—it varies widely between individuals. Some relatives with the same change have severe eye findings, while others have mild or no symptoms. Because of this variability, families may consider testing even before early symptoms of Exudative vitreoretinopathy 1 appear.
FZD4 gene changes: Most cases result from harmful changes in the FZD4 gene that alter how retinal blood vessels grow and mature. This genetic cause defines Exudative vitreoretinopathy 1.
Autosomal dominant pattern: Inheritance is usually autosomal dominant, meaning each child of a parent with the FZD4 change has a 50% chance to inherit it. This applies whether or not the parent has noticeable symptoms.
Reduced penetrance: Not everyone who inherits the FZD4 change will develop noticeable vision problems. Some carriers may have normal eye exams for years or only very subtle findings.
Variable expressivity: Among relatives with the same change, severity can range from tiny vessel differences to significant vision loss. The degree of change can even differ between a person’s two eyes.
De novo variants: Sometimes the FZD4 change appears for the first time in a child, with no prior family history of Exudative vitreoretinopathy 1. In these situations, the recurrence risk for future siblings is generally low.
Parental mosaicism: Rarely, a parent may carry the FZD4 change in a fraction of egg or sperm cells but not in blood testing. This can slightly increase the chance of another child with Exudative vitreoretinopathy 1 after an apparently new case.
Lifestyle risk factors
Exudative vitreoretinopathy 1 is a genetic retinal condition; lifestyle habits do not cause it, but they can influence symptoms, complications, and recovery from treatments. Focusing on how lifestyle affects Exudative vitreoretinopathy 1 can help reduce risks like vitreous hemorrhage and retinal detachment. Below are practical lifestyle risk factors for Exudative vitreoretinopathy 1 to consider with your eye specialist.
Nicotine and smoke toxins reduce retinal blood flow and can worsen ischemia that drives abnormal vessel growth. Avoiding smoking and vaping may lower the chance of vitreous hemorrhage or progression after treatment.
Blunt eye or head trauma from sports like boxing, basketball, or soccer can trigger retinal tears or detachments in fragile retinas. Choosing non-contact or well-protected activities lowers detachment risk.
Breath-holding with heavy lifting (Valsalva) can spike eye pressure and provoke vitreous hemorrhage. Using lighter loads, steady breathing, and avoiding straining reduces stress on vulnerable retinal vessels.
Large blood pressure swings stress retinal microvessels and may aggravate leakage or neovascular activity. Regular aerobic exercise and a lower-salt eating pattern help steady blood pressure and support retinal perfusion.
Risk prevention
Exudative vitreoretinopathy 1 is an inherited eye condition, so you can’t fully prevent it, but you can lower the chance of vision-threatening complications. The goal is early detection, quick treatment when needed, and protecting the eyes over a lifetime. Even if you can’t remove all risks, prevention can reduce their impact.
Schedule retinal exams starting in infancy and continue them regularly through adulthood. A retina specialist can spot early vessel changes or leakage before symptoms appear.
Parents, siblings, and children should have retinal exams, even if vision seems normal. Genetic counseling can help families understand inheritance and plan monitoring for future pregnancies.
Know early symptoms of Exudative vitreoretinopathy 1, like sudden flashes, new floaters, or a shadow in the side vision. Seek urgent eye care the same day if these appear.
Reduce risk of eye injury by avoiding high-impact contact sports and using protective eyewear when needed. Ask your eye doctor about safe activities and any sport-specific limits.
Transmission
Exudative vitreoretinopathy 1 is not contagious—you can’t catch it or pass it through casual contact. It’s most often inherited in an autosomal dominant way, meaning that when a parent carries the gene change, each child has a 50% chance of inheriting it. Severity varies, so people with Exudative vitreoretinopathy 1 in the same family may range from no symptoms to early vision problems. Sometimes the condition shows up for the first time in a child because of a new gene change, even when both parents see normally. If you have questions about the genetic transmission of Exudative vitreoretinopathy 1, a genetics professional can review your family’s risk and testing options.
When to test your genes
Consider genetic testing if you or a close relative has unexplained peripheral vision loss, retinal detachment, or is diagnosed with familial exudative vitreoretinopathy (FEVR). Test before pregnancy or in early childhood to guide screening, laser therapy timing, and protect vision in at‑risk relatives. Re‑test or expand panels if prior results were inconclusive.
Diagnosis
Exudative vitreoretinopathy 1 is usually diagnosed by looking for characteristic changes in the retina and then confirming with specialized tests. Getting a diagnosis is often a turning point toward answers and support. Doctors combine a careful eye exam with imaging and, when indicated, genetic tests to clarify the cause and guide next steps.
Doctors look for abnormal vessel patterns at the retina’s edges, exudates (leakage), and signs of pulling or detachment. These clinical features point toward exudative vitreoretinopathy and guide which tests to do next.
A fluorescein dye test shows areas without normal vessels and any leakage along the retinal edges. These imaging findings help distinguish this condition from retinopathy of prematurity and other causes.
Cross-sectional scans map the center of the retina to detect traction, fluid, or thinning. Detailed views help assess severity and plan treatment or monitoring.
If the view is blocked by bleeding or a cloudy lens, ultrasound helps identify retinal detachment and scar-like membranes. This is especially useful in infants or advanced disease.
Stages of Exudative vitreoretinopathy 1
Exudative vitreoretinopathy 1 is commonly described in stages that reflect how far changes in the retina have progressed. Early symptoms of exudative vitreoretinopathy 1 can be subtle, and many people have no noticeable vision changes in the early stages. Many people feel reassured knowing what their tests can—and can’t—show. Staging helps eye specialists decide on timing and type of treatment, and how closely to monitor each eye over time.
Stage 1
The outer retina has areas with underdeveloped blood vessels. This stage of exudative vitreoretinopathy 1 often causes no symptoms and is found during a detailed eye exam. Regular monitoring is usually recommended.
Stage 2
New, fragile vessels appear at the border of the underdeveloped area. These can leak a little, but vision often stays normal. Your doctor may see small deposits or subtle changes.
Stage 3
Fragile vessels grow onto the gel inside the eye and can leak, leading to swelling and scar tissue. Vision may blur or waver, and some notice new floaters or distortion. Treatment to reduce leakage or scarring may be discussed.
Stage 4
Scar tissue pulls on the retina, causing a partial detachment. Side vision or central vision can dim depending on which area lifts. Prompt specialist care is often needed.
Stage 5
The retina is fully detached. This late stage of exudative vitreoretinopathy 1 brings severe vision loss. Surgery may be considered, though results can vary.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many people with Exudative vitreoretinopathy 1 (EVR1), vision changes unfold slowly, starting with trouble seeing to the side or at night, and sometimes progressing to blurry central vision. Many people find that symptoms come and go in waves—stable for months or years, then shifting after a growth spurt, pregnancy, or another health stress. Severe complications like retinal detachment, bleeding in the eye, or glaucoma can occur, especially if the peripheral retina is very underdeveloped. EVR1 itself does not affect life span, but significant vision loss can impact independence, driving, and work, so staying ahead of eye changes matters.
Prognosis refers to how a condition tends to change or stabilize over time. In EVR1, outlook varies widely even within the same family. Some people maintain useful vision for decades with careful monitoring and timely laser or injection treatments, while others have early symptoms of exudative vitreoretinopathy 1 that progress more quickly and need surgery to reattach the retina. Episodes of leakage or new blood vessel growth can recur, but that doesn’t always mean permanent vision loss—prompt care often restores stability. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, including avoiding smoking, controlling blood pressure, and protecting eyes from injury.
Knowing what to expect can ease some of the worry. Regular exams with wide-field imaging help catch silent changes before vision drops, and small adjustments—like treating new weak areas of retina—can prevent bigger problems later. With ongoing care, many people maintain functional vision in at least one eye, and low-vision tools can keep reading, school, and work on track if vision falls. Talk with your doctor about what your personal outlook might look like, especially during times of rapid change such as adolescence or pregnancy, so your care plan can adjust before issues build.
Long-term effects
Vision changes in this condition often touch everyday tasks—reading fine print, moving around in dim light, or judging steps and curbs. Exudative vitreoretinopathy 1 can stay quiet for years or shift in spurts, and the two eyes may behave differently. Long-term effects vary widely, from mild peripheral changes to more serious central vision problems. Some people have stable eyesight, while others face episodes that need treatment to protect the retina.
Central or side vision can slowly decline over time, sometimes in steps. Changes may be subtle at first and then more noticeable during flare-ups.
The far edges of vision may narrow, making it harder to detect objects off to the side. This can affect night walking, sports, and driving.
Areas of thin or pulled retina can lift away, leading to sudden shadows or flashing lights. Detachments may recur and often need surgery to preserve vision.
Scar tissue can pull on the center of seeing (macula), causing distortion or waviness. Reading lines on a page may look bent or broken.
How is it to live with Exudative vitreoretinopathy 1?
Living with exudative vitreoretinopathy 1 can mean navigating changing vision—sometimes good days with usable sight, other times trouble with depth, night vision, or peripheral awareness that makes stairs, driving, or reading signs harder. Many build routines around lighting, contrast, and assistive tools like magnifiers or screen readers, and plan travel with extra time and orientation strategies to stay safe and independent. Family, friends, and classmates or coworkers often play a key role by offering rides, helping with visual tasks, and understanding that vision may fluctuate day to day. With low-vision rehabilitation, regular eye care, and practical adaptations at home and work, many find a steady rhythm that protects eye health while keeping daily life, school, and careers moving forward.
Treatment and drugs
Treatment for exudative vitreoretinopathy 1 focuses on protecting vision, preventing complications like retinal detachment, and addressing new blood vessel growth that can leak or bleed. Care often starts with careful monitoring, dilated eye exams, and imaging; when changes appear, doctors may use eye drops, laser therapy to seal leaky areas, or injections of anti-VEGF medicine to calm abnormal vessels. If the retina pulls away, surgery such as a scleral buckle or vitrectomy may be needed to reattach it and stabilize the eye. Treatment plans often combine several approaches, and timing matters—early symptoms of exudative vitreoretinopathy 1 like flashes, floaters, or sudden blur deserve urgent evaluation. Because the condition can run in families, sharing information with family can help others get checked and treated sooner if needed.
Non-drug treatment
Living with exudative vitreoretinopathy 1 can affect school, driving, and reading as vision shifts over time. Early symptoms of exudative vitreoretinopathy 1 can be subtle, so planned checkups and timely procedures matter. Non-drug treatments often lay the foundation for keeping vision stable, with options that range from in-clinic laser to practical vision support at home and school. Your eye team will tailor care by age, severity, and which eyes are involved.
Scheduled retinal exams and imaging track changes before they threaten central vision. Children and teens often need closer follow-up because the condition can progress as the eyes grow.
Laser seals areas with poor blood supply to reduce leakage and prevent fragile new vessels from forming. It is usually an outpatient procedure done with numbing drops or local anesthesia.
A freezing probe treats hard-to-reach areas when laser is not possible. This can help quiet leakage and shrink abnormal vessels in the retinal periphery.
A silicone band is placed around the eye to support the retina if it detaches. It can be combined with laser or cryotherapy to reduce the chance of another detachment.
Your genes may have an impact on how drugs work for you
Some people with exudative vitreoretinopathy 1 process eye medications differently because variants in genes that handle drug transport and breakdown can change dose needs or side‑effect risk. Genetic testing or careful dose‑finding with your clinician can help tailor safer, more effective treatment.
Pharmacological treatments
Medicines for exudative vitreoretinopathy 1 are mainly eye injections used alongside laser or surgery to calm leaky, fragile vessels and protect the retina. Because early symptoms of exudative vitreoretinopathy 1 can be subtle, medicines are usually paired with careful eye imaging and close follow‑up. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy). Your eye specialist will tailor choices to the eye’s stage, age, and response over time.
This anti-VEGF drug can shrink abnormal vessels and reduce leakage to help stabilize vision. It’s used off-label in FEVR and may need repeat doses with close monitoring for traction changes.
Similar to bevacizumab, it targets VEGF to calm new vessel growth and exudation. Doctors adjust treatment plans regularly to match how the retina responds over time.
This medicine traps VEGF and related signals to dry up retinal leakage and control bleeding. Some may need fewer injections over time, but careful follow-up is essential to watch for side effects like eye infection.
A steroid injection sometimes used for stubborn retinal swelling that doesn’t ease with anti-VEGF therapy. It’s less common and carries risks such as higher eye pressure and earlier cataract, so benefits and risks are weighed closely.
Genetic influences
In Exudative vitreoretinopathy 1, changes in a gene that helps the eye’s tiny blood vessels form can be inherited from a parent or happen for the first time in a child. Having a gene change doesn’t always mean you will develop the condition. Most families follow an autosomal dominant pattern: if a parent carries the gene change, each child has a 50% chance of inheriting it, yet the impact can range from no symptoms to serious vision problems—even within the same family. Less often, similar retinal problems come from changes in other genes with different inheritance patterns, so testing may look at a set of related genes. Because early symptoms of Exudative vitreoretinopathy 1 can be subtle or missed during routine checks, knowing your family history and considering genetic counseling can help with screening and timely care.
Is Exudative vitreoretinopathy 1 genetic?
Genetics play a major role in exudative vitreoretinopathy 1. Variants in several eye-development genes can disrupt retinal blood vessel growth, leading to vision problems. Inherited patterns vary (often X‑linked or autosomal dominant), and family history strongly guides testing and counseling.
Pharmacogenetics—how genetics influence drug effects
Because Exudative vitreoretinopathy 1 is linked to changes in a gene that guides blood vessel growth in the retina, genetics can shape care decisions, such as how closely to monitor and when to treat with laser or anti-VEGF eye injections. When early symptoms of Exudative vitreoretinopathy 1 show up, confirming the genetic cause can help doctors anticipate how the other eye and family members might be affected, though it doesn’t yet tell us which drug will work best. At present, there isn’t a validated pharmacogenetic test that predicts who will respond better to a specific anti-VEGF medicine, or what dose to use, in this condition. Some variability in response to eye injections or steroids is expected, and research is looking at whether certain gene changes influence this, but these tests are not part of routine care. Genetics is only one factor, and treatment choices still rely most on what the eye exam and imaging show at that moment. Knowing the exact gene change can still be useful for long-term planning and for eligibility in clinical trials of targeted therapies as they emerge.
Interactions with other conditions
Living with Exudative vitreoretinopathy 1 (often called FEVR) can be more complicated when other eye or blood vessel conditions are also present. Diabetes, high blood pressure, and blood disorders such as sickle cell disease all affect the retina’s circulation, and when they occur alongside FEVR they may increase the risk of leakage, scarring, or sudden bleeding that threatens vision. Ear and bone features are uncommon in Exudative vitreoretinopathy 1, but related conditions caused by changes in the same biological pathway have been linked with hearing loss or low bone density, so family history can help your care team decide what to screen for. Shared genetic variants may explain why certain conditions cluster together. FEVR can also be mistaken for retinopathy of prematurity; in someone born early who truly had ROP, scarring from ROP plus FEVR-like vessel changes can make treatment timing and follow-up especially important. If you notice new floaters, flashes, or a shadow in your side vision—early symptoms of Exudative vitreoretinopathy 1 getting more active—let your eye specialist know, particularly if you’re also managing another condition that affects the eyes.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of babies and young children who didn’t track faces well, bumped into things in dim light, or had “lazy” or wandering eyes that didn’t improve. In some families, more than one child needed eye patches, thick glasses, or surgery early in life. Doctors could see that the back layer of the eye—the retina—looked unusual, with blood vessels that seemed to stop short or tug on nearby tissue, but the reasons were unclear.
From early theories to modern research, the story of exudative vitreoretinopathy 1 shows how careful observation leads to answers. Before modern imaging, specialists documented cases where the retina pulled away from the eye wall (a retinal detachment) without the typical causes, like prematurity or injury. As reports gathered, they saw a pattern: otherwise healthy children and adults with a wide range of findings, from mild changes noticed on routine checks to severe vision loss in one or both eyes.
First described in the medical literature as a distinct form of inherited retinal blood vessel underdevelopment in the mid–20th century, it was later grouped under the broader name familial exudative vitreoretinopathy (FEVR). Over time, descriptions became more precise as wide‑field photography and angiography allowed doctors to map how far the retinal vessels extended and where leakage or scarring appeared. This explained why some people had only subtle vision changes while others developed pulling on the retina that led to folds, tears, or detachments.
Advances in genetics then clarified that exudative vitreoretinopathy 1 refers to one genetic subtype within FEVR. Researchers linked certain families to changes in a gene that helps guide how retinal vessels grow and maintain their connections. That discovery connected the clinic to the lab: the same signaling pathways were shown to act like dimmer switches for vessel growth, helping explain the patchy, incomplete vessel networks doctors had been seeing for decades.
With each decade, the picture broadened. Testing made it clear that severity varies widely—even within a single family. Some relatives have only subtle vessel changes that a specialist finds on exam; others have early symptoms of exudative vitreoretinopathy 1 in infancy. This variability reshaped care, encouraging screening of at‑risk family members and earlier monitoring to prevent complications.
In recent decades, awareness has grown that timely, tailored treatment—such as laser to areas without vessels, injections to quiet leakage, and surgery when needed—can protect vision. Today, the history of exudative vitreoretinopathy 1 continues to evolve as imaging sharpens, genetics expands, and long‑term follow‑up teaches which changes signal higher risk, guiding families and clinicians toward earlier, safer care.